Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes

References

• Back DJ, Tjia JF. (1991). Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32:624–626.
   PubMed Web of Science ®Google Scholar
• Barry AL, Brown SD. (1996). In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 40:1948–1949.
   PubMed Web of Science ®Google Scholar
• Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. (1997). Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 41:1840–1842.
   PubMed Web of Science ®Google Scholar
• Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, Hall SD. (2002). The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 53:67–74.
   PubMed Web of Science ®Google Scholar
• Chang HH, Lee NY, Ko WC, Lee HC, Yang YH, Wu CJ, Chang CM. (2010). Voriconazole inhibition of tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis. Int J Infect Dis 14:e348–e350.
   PubMed Web of Science ®Google Scholar
• Cogill JL, Taylor PJ, Westley IS, Morris RG, Lynch SV, Johnson AG. (1998). Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem 44:1942–1946.
   Google Scholar
• Ervine CM, Houston JB. (1994). Disposition of azole antifungal agents. III. Binding of fluconazole and other azoles in rat liver. Pharm Res 11:961–965.
   PubMedGoogle Scholar
• Furlan V, Parquin F, Penaud JF, Cerrina J, Ladurie FL, Dartevelle P, Taburet AM. (1998). Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. Transplant Proc 30:187–188.
   PubMed Web of Science ®Google Scholar
• Gibbs MA, Thummel KE, Shen DD, Kunze KL. (1999). Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180–187.
   PubMed Web of Science ®Google Scholar
• Grenier FC, Luczkiw J, Bergmann M, Lunetta S, Morrison M, Blonski D, Shoemaker K, Kobayashi M. (1991). A whole blood FK 506 assay for the IMx analyzer. Transplant Proc 23:2748–2749.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415.
   PubMed Web of Science ®Google Scholar
• Iwasaki K, Matsuda H, Nagase K, Shiraga T, Tokuma Y, Uchida K. (1993). Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 82:209–216.
   Google Scholar
• Jeong S, Nguyen PD, Desta Z. (2009). Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: Major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother 53:541–551.
   PubMed Web of Science ®Google Scholar
• Kostrubsky VE, Ramachandran V, Venkataramanan R, Dorko K, Esplen JE, Zhang S, Sinclair JF, Wrighton SA, Strom SC. (1999). The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 27:887–894.
   PubMed Web of Science ®Google Scholar
• Kramer MR, Amital A, Fuks L, Shitrit D. (2011). Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): Efficacy and drug interaction. Clin Transplant 25:E163–E167.
   PubMed Web of Science ®Google Scholar
• Kunze KL, Wienkers LC, Thummel KE, Trager WF. (1996). Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab Dispos 24:414–421.
   PubMed Web of Science ®Google Scholar
• Lazar JD, Wilner KD. (1990). Drug interactions with fluconazole. Rev Infect Dis 12 Suppl 3:S327–S333.
   PubMedGoogle Scholar
• Lomaestro BM, Piatek MA. (1998). Update on drug interactions with azole antifungal agents. Ann Pharmacother 32:915–928.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
   PubMed Web of Science ®Google Scholar
• Matthew D, Brennan B, Zomorodi K, Houston JB. (1993). Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. Pharm Res 10:418–422.
   Google Scholar
• Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P. (1992). Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 6:752–758.
   PubMed Web of Science ®Google Scholar
• Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. (2009). Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 44:371–374.
   PubMed Web of Science ®Google Scholar
• Murthy JN, Davis DL, Yatscoff RW, Soldin SJ. (1998). Tacrolimus metabolite cross-reactivity in different tacrolimus assays. Clin Biochem 31:613–617.
   Google Scholar
• Omar G, Whiting PH, Hawksworth GM, Humphrey MJ, Burke MD. (1997). Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther Drug Monit 19:436–445.
   PubMedGoogle Scholar
• Paterson DL, Singh N. (1999). Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 78:123–138.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA. (1998). In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 42:3242–3244.
   PubMed Web of Science ®Google Scholar
• Prasad TN, Stiff DD, Subbotina N, Zemaitis MA, Burckart GJ, Starzl TE, Venkataramanan R. (1994). FK 506 (Tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. Res Commun Chem Pathol Pharmacol 84:35–46.
   PubMedGoogle Scholar
• Sabo JA, Abdel-Rahman SM. (2000). Voriconazole: A new triazole antifungal. Ann Pharmacother 34:1032–1043.
   PubMed Web of Science ®Google Scholar
• Sanati H, Belanger P, Fratti R, Ghannoum M. (1997). A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 41:2492–2496.
   PubMed Web of Science ®Google Scholar
• Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. (1992). Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753–761.
   PubMed Web of Science ®Google Scholar
• Singh N, Wagener MM, Marino IR, Gayowski T. (2002). Trends in invasive fungal infections in liver transplant recipients: Correlation with evolution in transplantation practices. Transplantation 73:63–67.
   PubMed Web of Science ®Google Scholar
• Soltero L, Carbajal H, Rodríguez-Montalvo C, Valdés A. (2003). Coadministration of tacrolimus and ketoconazole in renal transplant recipients: Cost analysis and review of metabolic effects. Transplant Proc 35:1319–1321.
   Google Scholar
• Trifilio SM, Scheetz MH, Pi J, Mehta J. (2010). Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: Preemptive dose modification and therapeutic drug monitoring. Bone Marrow Transplant 45:1352–1356.
   PubMed Web of Science ®Google Scholar
• Van der Hoeven TA, Coon MJ. (1974). Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 249:6302–6310.
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. (1995). Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404–430.
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Zang S, Gayowski T, Singh N. (2002). Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 46:3091–3093.
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. (1994). In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222–1227.
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. (1996a). Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783–791.
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. (1996b). Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370–379.
   PubMed Web of Science ®Google Scholar
• Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. (1988). Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6 β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 263:424–436.
   PubMed Web of Science ®Google Scholar
• Yamano K, Yamamoto K, Kotaki H, Sawada Y, Iga T. (1999). Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver. Drug Metab Dispos 27:395–402.
   PubMed Web of Science ®Google Scholar
• Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. (2004). Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 57:298–309.
   PubMed Web of Science ®Google Scholar